C:\Program Files\Stnexp\Queries\10582826 (claim 2).str





chain nodes :
    13
ring nodes :
    1 2 3 4 5 6 7 8 9 10 11 12 17 18 19 20 21 22
ring/chain nodes :
    15
chain bonds :
    3-9 7-13 8-18
ring bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-22 18-19 19-20
    20-21 21-22
exact/norm bonds :
    7-8 7-12 7-13 8-9 8-18 9-10 10-11 11-12
exact bonds :
    3-9
normalized bonds :
    1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22
isolated ring systems :
    containing 1 : 7 :

Match level :
    1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
    12:Atom 13:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L1    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L2    SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10582826.str
```



```
chain nodes :
13
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12
chain bonds :
3-9  7-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12
exact/norm bonds :
7-8  7-12  7-13  8-9  9-10  10-11  11-12
exact bonds :
3-9
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:CLASS
```

```
L3      STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4   QUE L3 AND L1 NOT L2

=> d l4
L4 HAS NO ANSWERS
L1              SCR 1839
L2              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L4              QUE  L3 AND L1 NOT L2


=> s l4 sss sam
SAMPLE SEARCH INITIATED 14:00:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     4763 TO ITERATE

 42.0% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        91121 TO    99399
PROJECTED ANSWERS:            6846 TO     9252

L5           50 SEA SSS SAM L3 AND L1 NOT L2

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839
```

L6 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10582826 (a).str



chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
ring/chain nodes :
15
chain bonds :
3-9 7-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
7-8 7-12 7-13 8-9 9-10 10-11 11-12
exact bonds :
3-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 15:CLASS 16:Atom

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

```
L9   QUE L8 AND L6 NOT L7

=> d l9
L9 HAS NO ANSWERS
L6              SCR 1839
L7              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L8              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L9              QUE  L8 AND L6 NOT L7


=> s l9 sss sam
SAMPLE SEARCH INITIATED 14:03:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     4763 TO ITERATE

 42.0% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        91121 TO    99399
PROJECTED ANSWERS:            4009 TO     5897

L10          50 SEA SSS SAM L8 AND L6 NOT L7

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L11   SCREEN CREATED
```

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10582826 (claim 2).str



chain nodes :
13
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 17 18 19 20 21 22
ring/chain nodes :
15
chain bonds :
3-9 7-13 8-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-22
18-19 19-20 20-21 21-22
exact/norm bonds :
7-8 7-12 7-13 8-9 8-18 9-10 10-11 11-12
exact bonds :
3-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom

L13   STRUCTURE UPLOADED

```
=> que L13 AND L11 NOT L12

L14  QUE L13 AND L11 NOT L12

=> d l14
L14 HAS NO ANSWERS
L11             SCR 1839
L12             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L13             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L14             QUE  L13 AND L11 NOT L12


=> s l14 sss sam
SAMPLE SEARCH INITIATED 14:06:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      704 TO ITERATE

100.0% PROCESSED      704 ITERATIONS                                12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        12489 TO    15671
PROJECTED ANSWERS:              33 TO      447

L15          12 SEA SSS SAM L13 AND L11 NOT L12

=> => s l14 sss ful
FULL SEARCH INITIATED 14:07:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    13552 TO ITERATE

100.0% PROCESSED    13552 ITERATIONS                              221 ANSWERS
```

SEARCH TIME: 00.00.01

L16 221 SEA SSS FUL L13 AND L11 NOT L12

=> => s l16
L17 17 L16

=> d l17 1-17 bib,ab,hitstr

L17 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:1454797 CAPLUS
DN 148:79051
TI Preparation of diaryl pyrimidinones and related compounds as CB1 modulators
IN Li, Hongbin; Yuan, Jun; Wustrow, David J.
PA Neurogen Corporation, USA
SO PCT Int. Appl., 89pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007146761	A2	20071221	WO 2007-US70676	20070608
WO 2007146761	A3	20081030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2006-804451P P 20060612
OS MARPAT 148:79051
AB The title compds. I [A = CR1 or N; Ar1, Ar2 = (un)substituted Ph, naphthyl and 5-10 membered heteroaryl; R1 = H, OH, NO2, alkyl, etc.; R2 = alkenyl, cycloalkylalkyl, alkoxy, etc.] that may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and dependency disorders (no data), were prepared and disclosed. E.g., a multi-step synthesis of II, starting from 4-trifluoromethylaniline and 2-chlorobenzoyl chloride was described. Pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agent, and methods for using them to treat CB1 receptor-mediated disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.
IT 960320-37-0P
RL: PAC (Pharmacological activity); PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diaryl pyrimidinone compds. as CB1 receptor modulators for treating CB1 receptor-mediated diseases)
RN 960320-37-0 CAPLUS
CN Carbamic acid, N-[1-[2-(2-chlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 960321-57-7P 960321-58-8P 960321-59-9P
960321-60-2P 960321-61-3P 960321-62-4P
960321-63-5P 960321-64-6P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl pyrimidinone compds. as CB1 receptor modulators for treating CB1 receptor-mediated diseases)

RN 960321-57-7 CAPLUS
CN Carbamic acid, N-[2-[[2-(4-chloro-2-methylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]methylamino]ethyl]-N-methyl-, methyl ester (CA INDEX NAME)



RN 960321-58-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-[(2-hydroxy-3-methylbutyl)methylamino]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-59-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-chlorophenyl)-6-[4-[(1-methyl-1H-pyrazol-5-yl)carbonyl]-1-piperazinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-60-2 CAPLUS
CN 4(3H)-Pyrimidinone, 6-[4-[(3-fluorophenyl)methyl]-1-piperazinyl]-2-(2-methylphenyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-61-3 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-(ethylamino)- (CA INDEX NAME)



RN 960321-62-4 CAPLUS
CN Carbamic acid, N,N-dimethyl-, 1-[2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-azetidinyl ester (CA INDEX NAME)



RN 960321-63-5 CAPLUS
CN Methanesulfonamide, N-[1-[2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (CA INDEX NAME)



RN 960321-64-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-methylphenyl)-6-[4-(1H-1,2,4-triazol-1-yl)-1-piperidinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 960320-41-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diaryl pyrimidinone compds. as CB1 receptor modulators for treating CB1 receptor-mediated diseases)
RN 960320-41-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-chlorophenyl)-6-(4-thiomorpholinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 960320-39-2P 960320-42-7P 960320-44-9P
960320-45-0P 960320-46-1P 960320-49-4P
960320-50-7P 960320-51-8P 960320-52-9P
960320-54-1P 960320-56-3P 960320-57-4P
960320-60-9P 960320-61-0P 960320-62-1P
960320-63-2P 960320-64-3P 960320-65-4P
960320-66-5P 960320-69-8P 960320-70-1P
960320-71-2P 960320-72-3P 960320-73-4P
960320-74-5P 960320-75-6P 960320-76-7P
960320-77-8P 960320-78-9P 960320-79-0P
960320-80-3P 960320-81-4P 960320-82-5P
960320-83-6P 960320-84-7P 960320-85-8P
960320-86-9P 960320-87-0P 960320-88-1P
960320-89-2P 960320-90-5P 960320-91-6P
960320-92-7P 960320-93-8P 960320-94-9P
960320-95-0P 960320-96-1P 960320-97-2P
960320-98-3P 960320-99-4P 960321-00-0P
960321-01-1P 960321-02-2P 960321-03-3P
960321-04-4P 960321-05-5P 960321-06-6P
960321-07-7P 960321-08-8P 960321-09-9P
960321-10-2P 960321-11-3P 960321-12-4P
960321-13-5P 960321-14-6P 960321-15-7P
960321-16-8P 960321-17-9P 960321-18-0P
960321-22-6P 960321-26-0P 960321-27-1P
960321-31-7P 960321-32-8P 960321-33-9P
960321-34-0P 960321-39-5P 960321-40-8P
960321-41-9P 960321-42-0P 960321-43-1P
960321-44-2P 960321-46-4P 960321-47-5P
960321-52-2P 960321-53-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl pyrimidinone compds. as CB1 receptor modulators for treating CB1 receptor-mediated diseases)

RN 960320-39-2 CAPLUS

CN Propanamide, N-[1-[2-(2-chlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960320-42-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-chlorophenyl)-6-(1,1-dioxido-4-thiomorpholinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960320-44-9 CAPLUS
CN Propanamide, N-[1-[2-(2-chlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-45-0 CAPLUS
CN Propanamide, N-[1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960320-46-1 CAPLUS
CN Propanamide, N-[1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-49-4 CAPLUS
CN Carbamic acid, N-[1-[2-(4-chloro-2-methylphenyl)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 960320-50-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-(4-thiomorpholinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960320-51-8 CAPLUS
CN Carbamic acid, N-[1-[2-(2,4-difluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 960320-52-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-6-(4-thiomorpholinyl)- (CA INDEX NAME)



RN 960320-54-1 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-6-(1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 960320-56-3 CAPLUS
CN Propanamide, N-[1-[1,6-dihydro-2-(2-methylphenyl)-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960320-57-4 CAPLUS
CN Propanamide, N-[1-[1,6-dihydro-2-(2-methylphenyl)-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-60-9 CAPLUS
CN Acetamide, N-[1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-

oxo-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960320-61-0 CAPLUS
CN Carbamic acid, N-[1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 960320-62-1 CAPLUS
CN Carbamic acid, N-[1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960320-63-2 CAPLUS
CN Acetamide, N-[1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-2-methoxy- (CA INDEX NAME)



RN 960320-64-3 CAPLUS
CN Urea, N'-[1-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960320-65-4 CAPLUS
CN Propanamide, N-[1-[2-(2-fluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960320-66-5 CAPLUS
CN Propanamide, N-[1-[2-(2-fluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-69-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-(1,1-dioxido-4-thiomorpholinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960320-70-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-(1-oxido-4-thiomorpholinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960320-71-2 CAPLUS
CN Propanamide, N-[1-[2-(4-chloro-2-methylphenyl)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-72-3 CAPLUS
CN Propanamide, N-[1-[2-(4-chloro-2-methylphenyl)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960320-73-4 CAPLUS
CN Carbamic acid, N-[1-[2-(4-chloro-2-methylphenyl)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960320-74-5 CAPLUS
CN Propanamide, N-[1-[2-(2,4-difluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-75-6 CAPLUS
CN Propanamide, N-[1-[2-(2,4-difluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960320-76-7 CAPLUS
CN Carbamic acid, N-[1-[2-(2,4-difluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960320-77-8 CAPLUS
CN Urea, N'-[1-[2-(4-chloro-2-methylphenyl)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960320-78-9 CAPLUS
CN Urea, N'-[1-[2-(2,4-difluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960320-79-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-6-[4-(1-oxopropyl)-1-piperazinyl]- (CA INDEX NAME)



RN 960320-80-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)



RN 960320-81-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 960320-82-5 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-6-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]- (CA INDEX NAME)



RN 960320-83-6 CAPLUS
CN 1-Piperazinecarboxamide, 4-[1-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960320-84-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-6-[4-(1-oxopropyl)-1-piperazinyl]- (CA INDEX NAME)



RN 960320-85-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)



RN 960320-86-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 960320-87-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-6-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]- (CA INDEX NAME)



RN 960320-88-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960320-89-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-6-[4-(2-methylpropyl)-1-piperazinyl]- (CA INDEX NAME)



RN 960320-90-5 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-chlorophenyl)-6-(4-cyclobutyl-1-piperazinyl)-2-(2,4-dichlorophenyl)- (CA INDEX NAME)



RN 960320-91-6 CAPLUS
CN Propanamide, N-[1-[1-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-92-7 CAPLUS
CN Urea, N'-[1-[1-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-1,6-dihydro-6-

oxo-4-pyrimidinyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960320-93-8 CAPLUS
CN Carbamic acid, N-[1-[1-(4-chloro-2-fluorophenyl)-2-(2-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960320-94-9 CAPLUS
CN Propanamide, N-[1-[2-(4-chlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-95-0 CAPLUS
CN Urea, N'-[1-[2-(4-chlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960320-96-1 CAPLUS
CN Carbamic acid, N-[1-[2-(4-chlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960320-97-2 CAPLUS
CN Propanamide, N-[1-[2-(2-chloro-4-fluorophenyl)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960320-98-3 CAPLUS
CN Urea, N'-[1-[2-(2-chloro-4-fluorophenyl)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960320-99-4 CAPLUS
CN Carbamic acid, N-[1-[2-(2-chloro-4-fluorophenyl)-1-(4-chlorophenyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960321-00-0 CAPLUS
CN Propanamide, N-[1-[2-(2,4-dimethylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960321-01-1 CAPLUS
CN Urea, N'-[1-[2-(2,4-dimethylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960321-02-2 CAPLUS
CN Carbamic acid, N-[1-[2-(2,4-dimethylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960321-03-3 CAPLUS
CN Propanamide, N-[1-[2-(4-chloro-2-methylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960321-04-4 CAPLUS
CN Propanamide, N-[1-[2-(4-chloro-2-methylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960321-05-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-(2,6-dimethyl-4-morpholinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-06-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-[4-(2-methylpropyl)-1-piperazinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-07-7 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(4-cyclobutyl-1-piperazinyl)-2-(2,4-dichlorophenyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-08-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)



RN 960321-09-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-10-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-[2-(2,4-dichlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-N,N-dimethyl- (CA INDEX NAME)



RN 960321-11-3 CAPLUS
CN Propanamide, N-[1-[2-(4-chloro-2-methylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 960321-12-4 CAPLUS
CN Acetamide, N-[1-[2-(4-chloro-2-methylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960321-13-5 CAPLUS
CN Acetamide, N-[1-[2-(4-chloro-2-methylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methoxy- (CA INDEX NAME)



RN 960321-14-6 CAPLUS
CN Carbamic acid, N-[1-[2-(4-chloro-2-methylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 960321-15-7 CAPLUS
CN Carbamic acid, N-[1-[2-(4-chloro-2-methylphenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960321-16-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-(4-hydroxy-1-piperidinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-17-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-(4-fluoro-1-piperidinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-18-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-(4-oxo-1-piperidinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-22-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2,4-dichlorophenyl)-6-(4,4-difluoro-1-piperidinyl)-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-26-0 CAPLUS
CN Carbamic acid, N-[1-[2-(4-chlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 960321-27-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chloro-2-methylphenyl)-6-[4-(2-methylpropyl)-1-piperazinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-31-7 CAPLUS
CN Propanamide, N-[1-[2-(4-chloro-2-fluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960321-32-8 CAPLUS
CN Propanamide, N-[1-[2-(4-chloro-2-fluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-2-methyl- (CA INDEX NAME)



RN 960321-33-9 CAPLUS
CN Carbamic acid, N-[1-[2-(4-chloro-2-fluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 960321-34-0 CAPLUS
CN Carbamic acid, N-[1-[2-(4-chloro-2-fluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



RN 960321-39-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chloro-2-fluorophenyl)-6-[4-(1-oxopropyl)-1-piperazinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-40-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chloro-2-fluorophenyl)-6-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-41-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(4-chloro-2-fluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)



RN 960321-42-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-(4-chloro-2-fluorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (CA INDEX NAME)



RN 960321-43-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chloro-2-fluorophenyl)-6-[4-(2-methylpropyl)-1-piperazinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-44-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chloro-2-fluorophenyl)-6-[4-(1-methylpropyl)-1-piperazinyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 960321-46-4 CAPLUS
CN Methanesulfonamide, N-[1-[2-(4-chlorophenyl)-1,6-dihydro-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960321-47-5 CAPLUS
CN Methanesulfonamide, N-[1-[1,6-dihydro-2-(2-methylphenyl)-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]- (CA INDEX NAME)



RN 960321-52-2 CAPLUS
CN Carbamic acid, N-[1-[1,6-dihydro-2-(2-methylphenyl)-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 960321-53-3 CAPLUS
CN Carbamic acid, N-[1-[1,6-dihydro-2-(2-methylphenyl)-6-oxo-1-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]-4-piperidinyl]-, ethyl ester (CA INDEX NAME)



L17 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:329344 CAPLUS
DN 146:337904
TI Preparation of pyrimidine carboxamides as inhibitors of cytokines and COX-2
IN Tadiparthi, Ravikumar; Aggarwal, Pawan; Parameswaran, Venkatesan; Thirunavukkarasu, Sappanimuthu; Barik, Rajib; Rajagopal, Sriram; Reddy, Gaddam Om
PA Orchid Research Laboratories Limited, India
SO PCT Int. Appl., 75pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007031829	A2	20070322	WO 2006-IB2461	20060907
WO 2007031829	A3	20071108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005CH01302	A	20070727	IN 2005-CH1302	20050915
AU 2006290465	A1	20070322	AU 2006-290465	20060907
US 20070072876	A1	20070329	US 2006-516549	20060907
EP 1931642	A2	20080618	EP 2006-795441	20060907
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI IN 2005-CH1302	A	20050915		
WO 2006-IB2461	W	20060907		

OS MARPAT 146:337904
AB Title compds. represented by the formula I [wherein R = H, halo, amino, etc.; R1, R3 = independently H, SR6 or SOpR7; R2, R4 = independently H, hydroxy, halo, etc.; R5 = H, hydroxy, azido, etc.; and their derivs., analogs, tautomers, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compns. thereof] were prepared as Cyclooxygenase-2 (COX-2) inhibitors. For example, II was provided in a multi-step synthesis starting from 5-cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine. I were tested in vitro evaluation of COX-2 inhibition activity in human whole blood assay, COX-1 and COX-2 enzyme based assay, in vitro measurement of tumor necrosis factor alpha (TNF-α), and etc. Thus, I and their pharmaceutical compns. are useful for the prophylaxis or treatment of a pain disorder, inflammation, and immunol. diseases in a mammal, which are mediated by TNF-α, IL (1β, 1,6,8,12) and COX-2 activity.
IT 613663-83-5, 5-Cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine 812691-93-3, 5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-

oxo-1,6-dihydropyrimidine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidine carboxamides as inhibitors of cytokines and COX-2)

RN 613663-83-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-93-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



L17 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:300062 CAPLUS
DN 147:427365
TI Pyrazolopyrimidinone derivatives for the treatment of inflammation and immunological diseases, their preparation, pharmaceutical compositions, and use in therapy
IN Agarwal, Shiv Kumar; Ravikumar, Tadiparthi; Aggarwal, Pawan; Shivakumar, Savithiri
PA Orchid Chemicals & Pharmaceuticals Ltd., India
SO Indian Pat. Appl., 23pp.
CODEN: INXXBQ
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI IN 2004CH00316	A	20060113	IN 2004-CH316	20040406
PRAI IN 2004-CH316		20040406		

OS CASREACT 147:427365; MARPAT 147:427365
AB The invention relates to pyrazolo[3,4-d]pyrimidin-4-ones of general formula I, which are useful for the treatment of inflammation and immunol. diseases. In compds. I, Ar1 and Ar2 are independently selected from (un)substituted aryl, (un)substituted heteroaryl, and (un)substituted heterocyclyl; R1 is H, halo, OH, NH2, formyl, alkylamino, arylamino, acylamino, sulfonylamino, substituted C1-6 alkyl, (un)substituted acyl, (un)substituted aryl, (un)substituted aralkyl, (un)substituted heteroaryl, (un)substituted heteroarylalkyl, or (un)substituted heterocyclyl; and R2 is selected from H, halo, OH, nitro, azido, alkyl, (un)substituted alkoxy, (un)substituted aryloxy, (un)substituted aralkyl, (un)substituted heteroaryl, (un)substituted acyl, (un)substituted acyloxy, (un)substituted (di)alkylamino, (un)substituted heterocyclyl, etc.; including tautomers, stereoisomers, polymorphs, hydrates, solvates, and salts thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, as well as to the use of the compns. for the treatment of inflammation and immunol. diseases. Substitution of pyrimidinone II with hydrazine hydrate followed by intramol. heterocyclization gave pyrazolopyrimidinone III. The compds. of the invention, e.g., III, are inhibitors of cyclooxygenase-2 (no data).
IT 613663-83-5, 5-Cyano-1-(4-methylphenyl)-4-methylthio-2-(4-(methylthio)phenyl)-1,6-dihydropyrimidin-6-one 812691-93-3, 5-Cyano-1-(3,4-dimethylphenyl)-4-methylthio-2-(4-(methylthio)phenyl)-1,6-dihydropyrimidin-6-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of pyrazolopyrimidinone derivs. for the treatment of inflammation and immunol. diseases)
RN 613663-83-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-93-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



L17 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:14078 CAPLUS
DN 146:121982
TI Preparation of pyrazolopyrimidinone derivatives as inhibitors of production of cytokines for treatment of inflammation, cancer, etc.
IN Tadiparthi, Ravikumar; Pushpan, Simi; Rajagopal, Sriram; Barik, Rajib
PA Orchid Research Laboratories Limited, India
SO PCT Int. Appl., 46pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007000655	A2	20070104	WO 2006-IB1791	20060628
	WO 2007000655	A3	20070322		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	IN 2005CH00813	A	20080509	IN 2005-CH813	20050628
	EP 1896476	A2	20080312	EP 2006-765607	20060628
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008543968	T	20081204	JP 2008-519006	20060628
PRAI	IN 2005-CH813	A	20050628		
	WO 2006-IB1791	W	20060628		

OS MARPAT 146:121982
AB The title compds. I [Ar1, Ar2 = (un)substituted aryl, heteroaryl, heterocyclyl; R1 = H, hydroxyl, halo, etc.; R2 = H, hydroxy, nitro, etc.] are prepared Thus, 3-amino-5-(4-methylphenyl)-6-[4-(methylthio)phenyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one was prepared by from hydrazine hydrate and 5-cyano-1-(4-methylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one. In an in vitro assay using human peripheral blood mononuclear cells and lipopolysaccharide, compds. of this invention at 10 μM gave 29.8-87.8% inhibition of TNF-α production
IT 613663-83-5 812691-93-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidinone derivs. as inhibitors of production of cytokines for treatment of inflammation and cancer)
RN 613663-83-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-93-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



L17 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:1283525 CAPLUS
DN 146:45537
TI Preparation of pyrimidinedione derivatives for treating inflammatory diseases
IN Tadiparthi, Ravikumar; Aggarwal, Pawan; Reddy, Gaddam Om; Parameswaran, Venkatesan; Rajagopal, Iram, Sr.; Raghuveeraswaminathan, Sankaranarayanan
PA Orchid Research Laboratories Limited, India
SO PCT Int. Appl., 42pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006129181	A2	20061207	WO 2006-IB1448	20060602
WO 2006129181	A3	20071227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005CH00682	A	20070727	IN 2005-CH682	20050603
PRAI IN 2005-CH682	A	20050603		

OS CASREACT 146:45537; MARPAT 146:45537
AB Title compds. represented by the formula I [wherein X = O or S; ring A, B = (hetero)aryl; R = H, OH, amino or (halo)alkyl; R1, R3 = independently H, SR5 or SOpR6; R2, R4 = independently H, halo, OH, NO2, etc.; R5 = H, alkyl(halide), aryl or alkylester; R6 = amino, OH, halo, etc.; Y = -C(=NH)R8 or -C(=NR9)R8; R8, R9 = independently H, amino, azido, etc.; m, n = 0-4; p = 1 or 2], useful for treating inflammatory diseases mediated by cytokines such as TNF-α, IL-1, IL-6, IL-8 and IL-12, were prepared E.g., reaction of 5-cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine with methylamine gave II, which showed TNF-α inhibition with IC50 value of 2.6 μM. Pharmaceutical composition comprising the compound I is claimed.
IT 916451-81-5P, N-Methyl-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide 916451-82-6P, N-Methyl-1-(3,4-dimethylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide 916451-83-7P, N-Methyl-1-(4-isopropylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide 916451-84-8P, N-Methyl-1-(3,4,5-trimethoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide 916451-85-9P 916451-88-2P 916451-89-3P, 1-(4-Chlorophenyl)-N-methyl-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide 916451-90-6P 916451-92-8P 916451-93-9P 916451-94-0P, 2-(4-Methoxyphenyl)-N-methyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboximidamide 916452-00-1P

916452-01-2P 916452-02-3P,
2-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-1-phenyl-1,6-dihydropyrimidine-5-carboximidamide 916452-03-4P,
2-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-1-(4-methylphenyl)-1,6-dihydropyrimidine-5-carboximidamide 916452-04-5P
, 2-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-1-(3,4-dimethylphenyl)-1,6-dihydropyrimidine-5-carboximidamide
916452-05-6P, 2-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-1-(4-fluorophenyl)-1,6-dihydropyrimidine-5-carboximidamide
916452-07-8P, 1-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(4-methylphenyl)-1,6-dihydropyrimidine-5-carboximidamide
916452-08-9P, 1-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(3,4-dimethylphenyl)-1,6-dihydropyrimidine-5-carboximidamide
916452-09-0P, 1-[4-(Aminosulfonyl)phenyl]-N-methyl-4-(methylthio)-6-oxo-2-(4-isopropylphenyl)-1,6-dihydropyrimidine-5-carboximidamide
916452-15-8P, 2-(4-Methylthiophenyl)-N-methyl-4-(1-methylhydrazino)-1-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-5-carboximidamide 916452-16-9P 916452-17-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinedione derivs. for treating inflammatory diseases)

RN 916451-81-5 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916451-82-6 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916451-83-7 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916451-84-8 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 916451-85-9 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-(4-ethylphenyl)-1,6-dihydro-N-methyl-4-

(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916451-88-2 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylamino)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916451-89-3 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-(4-chlorophenyl)-1,6-dihydro-N-methyl-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916451-90-6 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 916451-92-8 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-(4-fluorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916451-93-9 CAPLUS
CN 5-Pyrimidinecarboximidamide, 2-(4-fluorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916451-94-0 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-2-(4-methoxyphenyl)-N-methyl-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916452-00-1 CAPLUS
CN 5-Pyrimidinecarboximidamide, 2-[4-(dimethylamino)phenyl]-1-(3,4-dimethylphenyl)-1,6-dihydro-N-(2-hydroxyethyl)-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 916452-01-2 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-4-(methylthio)-1,2-bis[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916452-02-3 CAPLUS
CN 5-Pyrimidinecarboximidamide, 2-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo-1-phenyl- (CA INDEX NAME)



RN 916452-03-4 CAPLUS
CN 5-Pyrimidinecarboximidamide, 2-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-1-(4-methylphenyl)-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 916452-04-5 CAPLUS
CN 5-Pyrimidinecarboximidamide, 2-[4-(aminosulfonyl)phenyl]-1-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 916452-05-6 CAPLUS
CN 5-Pyrimidinecarboximidamide, 2-[4-(aminosulfonyl)phenyl]-1-(4-fluorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 916452-07-8 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-2-(4-methylphenyl)-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 916452-08-9 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-[4-(aminosulfonyl)phenyl]-2-(3,4-dimethylphenyl)-1,6-dihydro-N-methyl-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 916452-09-0 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-[4-(aminosulfonyl)phenyl]-1,6-dihydro-N-methyl-2-[4-(1-methylethyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 916452-15-8 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-N-methyl-4-(1-methylhydrazinyl)-1-(4-methylphenyl)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916452-16-9 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1-(4-chlorophenyl)-1,6-dihydro-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 916452-17-0 CAPLUS
CN 5-Pyrimidinecarboximidamide, 1,6-dihydro-1-(4-methoxyphenyl)-N-methyl-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



IT 613663-83-5, 5-Cyano-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine 812691-92-2, 5-Cyano-1-(4-isopropylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine 812691-93-3, 5-Cyano-1-(3,4-dimethylphenyl)-4-(methylthio)-6-oxo-2-(pyridin-3-yl)-1,6-dihydropyrimidine 812691-96-6, 5-Cyano-1-(3,4,5-trimethoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1,6-dihydropyrimidine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidinedione derivs. for treating inflammatory diseases)

RN 613663-83-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-92-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-93-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-96-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



L17 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:411890 CAPLUS
DN 144:450725
TI Preparation of pyrazolopyrimidinones and analogs, and their compositions as cannabinoid CB1 receptor inhibitors
IN Liu, Hong; He, Xiaohui; Choi, Ha-Soon; Yang, Kunyong; Woodmansee, David; Wang, Zhicheng; Ellis, David Archer; Wu, Baogen; He, Yun; Nguyen, Truc Ngoc
PA Irm LLC, Bermuda
SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006047516	A2	20060504	WO 2005-US38361	20051026
	WO 2006047516	A3	20061012		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005299421	A1	20060504	AU 2005-299421	20051026
	CA 2581225	A1	20060504	CA 2005-2581225	20051026
	EP 1807429	A2	20070718	EP 2005-813001	20051026
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
	CN 101048408	A	20071003	CN 2005-80036890	20051026
	JP 2008518016	T	20080529	JP 2007-539039	20051026
	BR 2005017015	A	20080930	BR 2005-17015	20051026
	IN 2007DN02514	A	20070803	IN 2007-DN2514	20070403
	MX 200704936	A	20070625	MX 2007-4936	20070424
	KR 2007057980	A	20070607	KR 2007-709370	20070425
	NO 2007002352	A	20070531	NO 2007-2352	20070507
PRAI	US 2004-622508P	P	20041026		
	US 2005-672670P	P	20050418		
	WO 2005-US38361	W	20051026		

The instant application is entitled to the priority date of the provisional application filed 12/19/2003

OS CASREACT 144:450725; MARPAT 144:450725
AB Title compds. I [Y = O, NH and derivs., S; R1 = (un)substituted Ph, heteroaryl, cycloalkyl, benzyl; R2 = (un)substituted Ph, OPh, heterocycloalkyl, heteroaryl; R3 = H, halo, OH, CN, etc.; R4 = (un)substituted hetero/aryl, alkyl, etc.; and their pharmaceutically acceptable salts, hydrates, solvates and isomers; with the exception of certain compds.] were prepared as selective cannabinoid CB1 receptor inhibitors. Thus, II was prepared, in 3 steps, starting from 5-amino-1-phenyl-1H-pyrazole-4-carboxylic acid Et ester and 2,4-dichlorobenzoyl chloride. Preferred compds. I showed a 100 fold selectivity for CB1 over CB2 receptor. Pharmaceutical compns. comprising I are useful for preventing and treating diseases or disorders associated

with the activity of CB1 receptor, e.g. metabolic disorders.

IT 885619-00-1P, 1-(4-Bromophenyl)-2-(2-fluorophenyl)-4-methylsulfanyl-6-oxo-1,6-dihydropyrimidine-5-carbonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolopyrimidinones and analogs as CB1 inhibitors)

RN 885619-00-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(4-bromophenyl)-2-(2-fluorophenyl)-1,6-dihydro-4-(methylthio)-6-oxo- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:406715 CAPLUS
DN 144:468112
TI Suzuki coupling at the 2-position of densely functionalized pyrimidones
AU Colarusso, Stefania; Girardin, Melina; Conte, Immacolata; Narjes, Frank
CS IRBM-Merck Research Laboratories Rome, Rome, 00040, Italy
SO Synthesis (2006), (8), 1343-1350
CODEN: SYNTBF; ISSN: 0039-7881
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 144:468112
AB A variety of Et 1-substituted 2-aryl-5-ethoxy-6-oxo-1,6-dihydropyrimidine-4-carboxylates were synthesized by efficient thermal or microwave-promoted Suzuki coupling of 2-chloro-N1-substituted precursors.
IT 886221-69-8P 886221-70-1P 886221-71-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2-aryldihydropyrimidinecarboxylates via palladium catalyzed thermal or microwave-promoted Suzuki coupling of chloro-substituted pyrimidinone intermediate with arylboronic acids)
RN 886221-69-8 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-2-(2-methylphenyl)-6-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 886221-70-1 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 5-ethoxy-1,6-dihydro-2-(4-methoxyphenyl)-6-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 886221-71-2 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-(2,6-dimethylphenyl)-5-ethoxy-1,6-dihydro-6-oxo-1-phenyl-, ethyl ester (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1215763 CAPLUS
DN 143:477975
TI Preparation of pyrimidinones and quinazolinones as calcilytic compounds
IN Luengo, Juan I.; Marquis, Robert W., Jr.; Xie, Ren; Yamashita, Dennis S.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005108376	A1	20051117	WO 2005-US15224	20050503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1742924	A1	20070117	EP 2005-744198	20050503
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007536239	T	20071213	JP 2007-511482	20050503
PRAI US 2004-568585P	P	20040506		
WO 2005-US15224	W	20050503		

The instant application is eligible to the priority date of 12/19/03

OS CASREACT 143:477975; MARPAT 143:477975
AB The title compds. I [R1, R2 = H, halo, CN, etc.; or R1 and R2 may be bonded together to form a carbocyclic, heterocylic, aryl or heteroaryl ring; R3 = aryl or heteroaryl group which may have 1-5 substituents each selected from H, halo, CN, CF3, etc.; R4 = aryl which may have 1-3 substituents consisting of H, halo, CN, CF3, etc.; X = O or S], useful for treating a disease or disorder characterized by an abnormal bone or mineral homeostasis, were prepared E.g., a multi-step synthesis of 2-(2-hydroxyphenyl)-3-(4-isopropylphenyl)-5,6,7,8-tetrahydro-3H-quinazolin-4-one, starting from Et 2-aminocyclohex-1-enecarboxylate and 2-benzyloxybenzoyl chloride, was given. The methods for treating diseases or disorders such as osteosarcoma, periodontal disease, fracture healing, osteoarthritis, joint replacement, rheumatoid arthritis, Paget's disease, humoral hypercalcemia, malignancy and osteoporosis by administering the compound I alone or in combination with anti-resorptive agents are disclosed.
IT 869564-58-9P 869564-60-3P 869564-62-5P
869564-64-7P 869564-66-9P 869564-68-1P
869564-70-5P 869564-72-7P 869564-74-9P
869564-76-1P 869564-98-7P 869564-99-8P
869565-00-4P 869565-01-5P 869565-02-6P
869565-03-7P 869565-04-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinones and quinazolinones as calcilytic compds.)

RN 869564-58-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-ethyl-2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-60-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-ethyl-2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-62-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-methylpropyl)- (CA INDEX NAME)



RN 869564-64-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-methylpropyl)- (CA INDEX NAME)



RN 869564-66-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-68-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-5,6-dimethyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-70-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-propyl- (CA INDEX NAME)



RN 869564-72-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-butyl-2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-74-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-phenyl- (CA INDEX NAME)



RN 869564-76-1 CAPLUS
CN 4(3H)-Pyrimidinone, 5-benzo[b]thien-2-yl-2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-98-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-benzo[b]thien-2-yl-2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-99-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-thienyl)- (CA INDEX NAME)



RN 869565-00-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-thienyl)- (CA INDEX NAME)



RN 869565-01-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(5-methyl-2-thienyl)- (CA INDEX NAME)



RN 869565-02-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(5-methyl-2-thienyl)- (CA INDEX NAME)



RN 869565-03-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869565-04-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-fluoro-2-hydroxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



IT 869564-88-5P 869564-94-3P 869564-95-4P
869564-96-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinones and quinazolinones as calcilytic compds.)
RN 869564-88-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(3-fluoro-2-methoxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-(2-methylpropyl)- (CA INDEX NAME)



RN 869564-94-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-methoxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-95-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-bromo-2-(2-methoxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 869564-96-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-methoxyphenyl)-6-methyl-3-[4-(1-methylethyl)phenyl]-5-phenyl- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1075505 CAPLUS
DN 143:367312
TI Preparation of novel condensed pyrimidones as cyclooxygenase inhibitors
IN Agarwal, Shiv Kumar; Tadiparthi, Ravi Kumar; Aggarwal, Pawan; Shivkumar, Savithri
PA Orchid Chemicals & Pharmaceuticals Ltd., India
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005091711	A2	20051006	WO 2005-IB736	20050322
WO 2005091711	A3	20060309		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2004CH00270	A	20051202	IN 2004-CH270	20040324
PRAI IN 2004-CH270	A	20040324		

OS CASREACT 143:367312; MARPAT 143:367312
AB The title compds. I [X = O, S; Ar1, Ar2 = (un)substituted aryl, heteroaryl, heterocyclyl; R1, R2 = H, OH, NO2, etc.], useful for lowering plasma concns. of cytokines, and for decreasing cyclooxygenase activity, were prepared Thus, reacting guanidine.HCl with 5-cyano-1-(4-methylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one in the presence of anhydrous K2CO3 in DMF afforded 23% I [X = O; Ar1 = 4-MeC6H4; Ar2 = 4-(MeS)C6H4; R1, R2 = NH2] which showed 29% COX-2 inhibition and 53% IL-6 inhibition. The present invention relates also to the pharmaceutically acceptable salts and pharmaceutically acceptable compns. containing compds. I.
IT 613663-83-5, 5-Cyano-1-(4-methylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one 812691-92-2, 5-Cyano-1-(4-isopropylphenyl)-4-methylthio-2(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one 812691-93-3, 5-Cyano-1-(3,4-dimethylphenyl)-4-methylthio-2-(4-methylthiophenyl)-1,6-dihydropyrimidin-6-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel condensed pyrimidones as cyclooxygenase inhibitors)
RN 613663-83-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-92-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-93-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:588550 CAPLUS
DN 143:115555
TI Preparation of 2-phenylpyrimidinone mitotic kinesin inhibitors
IN Arrington, Kenneth L.; Fraley, Mark E.; Hartman, George D.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English

Applicant's

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005060654	A2	20050707	WO 2004-US42171	20041215
	WO 2005060654	A3	20051208		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004305069	A1	20050707	AU 2004-305069	20041215
	CA 2547209	A1	20050707	CA 2004-2547209	20041215
	EP 1697331	A2	20060906	EP 2004-814365	20041215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1898215	A	20070117	CN 2004-80038124	20041215
	JP 2007518711	T	20070712	JP 2006-545404	20041215
	IN 2006DN02999	A	20070803	IN 2006-DN2999	20060525
	US 20070129356	A1	20070607	US 2006-582826	20060614
PRAI	US 2003-531554P	P	20031219		
	WO 2004-US42171	W	20041215		

OS CASREACT 143:115555; MARPAT 143:115555
AB Title compds. I [R1 = H, alkyl, aryl, alkenyl, etc.; R2 = acyl, carboxy, etc.; R3a-3b = H, acyl, alkyl, etc.; p = 1-3] are prepared For instance, 2-(2-bromophenyl)-3-(3-fluoro-4-methylphenyl)pyrimidin-4(3H)-one (II) is prepared in 3 steps from 2-bromobenzonitrile, 3-fluoro-4-methylaniline, DMF di-Me acetal and trimethylsilylketene. II exhibits IC50 ≤ 50 μM for KSP kinesin. I are useful for the treatment of cancer.
IT 857086-87-4P, 2-(2-Bromophenyl)-3-(3-fluoro-4-methylphenyl)pyrimidin-4(3H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-phenylpyrimidinone mitotic kinesin inhibitors)
RN 857086-87-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(2-bromophenyl)-3-(3-fluoro-4-methylphenyl)- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:1127094 CAPLUS
DN 142:74592
TI Preparation of novel pyrimidones for treating inflammation and immunol. diseases
IN Agarwal, Shiv Kumar; Tadiparthi, Ravikumar; Aggarwal, Pawan; Shivakumar, Savithiri; Dey, Debendranath; Nag, Biswajit
PA Orchid Chemical & Pharmaceuticals Limited, India
SO U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 409,045. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040259891	A1	20041223	US 2004-827368	20040420
	US 7365069	B2	20080429		
	IN 2002MA00266	A	20050304	IN 2002-MA266	20020410
	US 20030225075	A1	20031204	US 2003-409045	20030409
	US 20060194799	A1	20060831	US 2006-414229	20060501
	US 7399760	B2	20080715		
PRAI	IN 2002-MA266	A	20020410		
	US 2003-409045	A2	20030409		
	US 2003-409153	A3	20030409		

OS MARPAT 142:74592
AB The title compds. [I; X = O, S, NR (R = H, OH, acyl, etc.); A, B = (hetero)aryl; R1, R3 = H, SR7, SOpR8 (R7 = H, alkyl, aryl; R8 = halo, alkyl, NH2, acylamino, arylamino, aryl; p = 1-2); R2, R4 = H, halo, OH, etc.; R5, R6 = H, halo, OH, NO2, etc.; n, m = 0-4], useful for treating inflammation and immunol. diseases mediated by cytokines such as TNF-α, IL-1, IL-6, IL-1β, IL-8 and cyclooxygenase such as COX-2 and COX-3, were prepared Thus, reacting Et 2-cyano-3,3-dimethylthioacrylate with N-(4-methylthiophenyl)-4-fluorobenzamidine (preparation given) afforded II which showed 53.38% COX-2 inhibition. The pharmaceutical compns. comprising the compound I are disclosed.
IT 613663-79-9P 613663-83-5P 812691-93-3P
812692-27-6P 812692-31-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel pyrimidones for treating inflammation and immunol. diseases)
RN 613663-79-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-83-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-93-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-27-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 1,6-dihydro-1-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-31-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylsulfonyl)-1-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



IT 613663-78-8P 613663-81-3P 613663-82-4P
613663-84-6P 613663-85-7P 613663-95-9P
812691-92-2P 812691-94-4P 812691-95-5P
812691-96-6P 812691-97-7P 812691-98-8P
812691-99-9P 812692-01-6P 812692-02-7P
812692-03-8P 812692-04-9P 812692-05-0P
812692-07-2P 812692-24-3P 812692-25-4P
812692-26-5P 812692-28-7P 812692-29-8P
812692-30-1P 812692-32-3P 812692-33-4P
812692-34-5P 812692-35-6P 812692-36-7P
812692-37-8P 812692-38-9P 812692-39-0P
812692-41-4P 812692-42-5P 812692-70-9P
812692-71-0P 812692-72-1P 812692-73-2P
812692-74-3P 812692-75-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel pyrimidones for treating inflammation and immunol. diseases)
RN 613663-78-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-chlorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-81-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 613663-82-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-84-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 613663-85-7 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-95-9 CAPLUS
CN Benzenesulfonamide, 4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]- (CA INDEX NAME)



RN 812691-92-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-94-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-[4-(1-methylethyl)phenyl]-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 812691-95-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 812691-96-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-1-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 812691-97-7 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-ethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-98-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-bromophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812691-99-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methoxyphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-01-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-chlorophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-02-7 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(2,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-03-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-2-(4-methylphenyl)-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-04-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-ethoxyphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-05-0 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-[4-(1,1-dimethylethyl)phenyl]-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-07-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-butylphenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-24-3 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 812692-25-4 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 812692-26-5 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-, ethyl ester (CA INDEX NAME)



RN 812692-28-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo-4-(1-piperazinyl)- (CA INDEX NAME)



RN 812692-29-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 1,6-dihydro-4-(methylamino)-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-30-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(4-morpholinyl)-6-oxo- (CA INDEX NAME)



RN 812692-32-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylamino)-1-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-33-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-1,6-dihydro-1-[4-(methylsulfonyl)phenyl]-4-(4-morpholinyl)-6-oxo- (CA INDEX NAME)



RN 812692-34-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-35-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-4-hydroxy-1-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-36-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-37-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylamino)-1-(4-methylphenyl)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-38-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylamino)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-39-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylamino)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 812692-41-4 CAPLUS
CN Benzenesulfonyl chloride, 4-[5-cyano-1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-pyrimidinyl]- (CA INDEX NAME)



RN 812692-42-5 CAPLUS
CN Benzenesulfonyl chloride, 4-[5-cyano-2-(4-ethoxyphenyl)-4-(methylthio)-6-oxo-1(6H)-pyrimidinyl]- (CA INDEX NAME)



RN 812692-70-9 CAPLUS

CN Acetamide, N-[[4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 812692-71-0 CAPLUS
CN Acetamide, N-[[4-[5-cyano-1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 812692-72-1 CAPLUS
CN Acetamide, N-[[4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 812692-73-2 CAPLUS
CN Acetamide, N-[[4-[5-cyano-1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]-2,2,2-trifluoro- (CA INDEX NAME)



RN 812692-74-3 CAPLUS
CN Benzamide, N-[[4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]- (CA INDEX NAME)



RN 812692-75-4 CAPLUS
CN Benzamide, N-[[4-[5-cyano-1-(3,4-dimethylphenyl)-1,6-dihydro-4-(methylthio)-6-oxo-2-pyrimidinyl]phenyl]sulfonyl]- (CA INDEX NAME)



IT 812692-69-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel pyrimidones for treating inflammation and immunol. diseases)
RN 812692-69-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-ethoxyphenyl)-1,6-dihydro-4-(methylthio)-6-

oxo-1-phenyl- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:818406 CAPLUS
DN 139:323531
TI Preparation of novel pyrimidones for treating inflammation and immunol. diseases
IN Agarwal, Shiv Kumar; Tadiparthi, Ravikumar; Aggarwal, Pawan; Shivakumar, Savithiri; Dey, Debendranath; Nag, Biswajit
PA Orchid Chemicals & Pharmaceuticals Limited, India
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084938	A2	20031016	WO 2003-IB1306	20030410
	WO 2003084938	A3	20040205		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IN 2002MA00266	A	20050304	IN 2002-MA266	20020410
	US 20030232813	A1	20031218	US 2003-409161	20030409
	US 20040009975	A1	20040115	US 2003-409153	20030409
	US 7101873	B2	20060905		
	CA 2481825	A1	20031016	CA 2003-2481825	20030410
	AU 2003216592	A1	20031020	AU 2003-216592	20030410
	EP 1492774	A2	20050105	EP 2003-712500	20030410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1656080	A	20050817	CN 2003-812546	20030410
	JP 2005535570	T	20051124	JP 2003-582135	20030410
	IN 2004CH00353	A	20060526	IN 2004-CH353	20040419
	US 20060194799	A1	20060831	US 2006-414229	20060501
	US 7399760	B2	20080715		
	IN 2006CH02100	A	20081128	IN 2006-CH2100	20061113
	IN 2006CH02101	A	20081128	IN 2006-CH2101	20061113
PRAI	IN 2002-MA266	A	20020410		
	US 2003-409153	A3	20030409		
	WO 2003-IB1306	W	20030410		

OS MARPAT 139:323531
AB Th title compds. [I; X = O, S, NR (R = H, OH, acyl, etc.); A, B = (hetero)aryl; R1, R3 = SR7, SOpR8 (R7 = alkyl, aryl; R8 = alkyl, NH2, aryl; p = 1-2); R2, R4 = H, halo, OH, etc.; R5, R6 = H, halo, OH, NO2, etc.; n, m = 0-2], useful for treating inflammation and immunol. diseases mediated by cytokines such as TNF-α, IL-1, IL-6, IL-1β, IL-8 and cyclooxygenase such as COX-2 and COX-3, were prepared and formulated. Thus, reacting Et 2-cyano-3,3-dimethylthioacrylate with N-(4-methylthiophenyl)-4-fluorobenzamidine (preparation given) afforded II which showed 53.38% COX-2 inhibition. Pharmaceutical composition comprising the compound I is claimed.

IT 613663-78-8P 613663-79-9P 613663-81-3P
613663-82-4P 613663-83-5P 613663-84-6P
613663-85-7P 613663-92-6P 613663-93-7P
613663-94-8P 613663-95-9P 613663-96-0P
613663-97-1P 613663-98-2P 613664-00-9P
613664-01-0P 613664-02-1P 613664-03-2P
613664-04-3P 613664-05-4P 613664-07-6P
613664-09-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel pyrimidones for treating inflammation and immunol. diseases)

RN 613663-78-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-chlorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-79-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-81-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 613663-82-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-83-5 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-84-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 613663-85-7 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-92-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-1,6-dihydro-1-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 613663-93-7 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylsulfonyl)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-94-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-1-(4-methylphenyl)-4-(methylsulfonyl)-2-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613663-95-9 CAPLUS
CN Benzenesulfonamide, 4-[5-cyano-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo-2-pyrimidinyl]- (CA INDEX NAME)



RN 613663-96-0 CAPLUS
CN Benzenesulfonamide, 4-[5-cyano-2-(4-fluorophenyl)-4-(methylthio)-6-oxo-1(6H)-pyrimidinyl]- (CA INDEX NAME)



RN 613663-97-1 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 1,6-dihydro-1-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 613663-98-2 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 2-(4-fluorophenyl)-1,6-dihydro-1-(4-methylphenyl)-4-(methylthio)-6-oxo- (CA INDEX NAME)



RN 613664-00-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenyl)-1,6-dihydro-4-(methylthio)-1-[4-(methylthio)phenyl]-6-oxo- (CA INDEX NAME)



RN 613664-01-0 CAPLUS
CN 4(3H)-Pyrimidinone, 5-chloro-2-(4-chlorophenyl)-6-(methylthio)-3-[4-(methylthio)phenyl]- (CA INDEX NAME)



RN 613664-02-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chlorophenyl)-6-(methylthio)-3-[4-(methylthio)phenyl]- (CA INDEX NAME)



RN 613664-03-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chlorophenyl)-3-[4-(methylthio)phenyl]- (CA INDEX NAME)



RN 613664-04-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-methylphenyl)-6-(methylthio)-2-[4-(methylthio)phenyl]- (CA INDEX NAME)



RN 613664-05-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(4-methylphenyl)-2-[4-(methylthio)phenyl]- (CA INDEX NAME)



RN 613664-07-6 CAPLUS
CN Benzenesulfonamide, 4-[5-cyano-2-(4-methylphenyl)-4-(methylthio)-6-oxo-1(6H)-pyrimidinyl]- (CA INDEX NAME)



RN 613664-09-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1-(4-fluorophenyl)-1,6-dihydro-2-[4-(methylsulfonyl)phenyl]-4-(methylthio)-6-oxo- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:33216 CAPLUS
DN 136:340653
TI A facile synthesis of 4(3H)-pyrimidinones via [4+2] cycloaddition utilizing (trimethylsilyl)ketene
AU Arai, Shigeru; Sakurai, Takuya; Asakura, Hitomi; Fuma, Shin-Ya; Shioiri, Takayuki; Aoyama, Toyohiko
CS Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, 467-8603, Japan
SO Heterocycles (2001), 55(12), 2283-2287
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 136:340653
AB The [4+2]cycloaddn. reaction utilizing (trimethylsilyl)ketene with 1,3-diaza-1,3-dienes smoothly proceeded to give the desired cycloadducts, 4(3H)-pyrimidinones, in moderate to high yields. The 1,3-diaza-1,3-dienes included N-[(dimethylamino)methylene]-N'-phenylbenzenecarboximidamide, N-[(dimethylamino)methylene]-N'-(4-methylphenyl)benzenecarboximidamide, N-[(dimethylamino)methylene]-4-methyl-N'-phenylbenzenecarboximidamide, N-[(dimethylamino)methylene]-N'-phenyl-2-naphthalenecarboximidamide, [(dimethylamino)methylene]phenylcarbamimidothioic acid Me ester, and similar compds. For example, the cycloaddn. of (trimethylsilyl)ketene with N-[(dimethylamino)methylene]-N'-phenylbenzenecarboximidamide gave 2,3-diphenyl-4(3H)-pyrimidinone (I) in 94% yield in Et acetate. When the reaction was run in toluene as solvent the yield of I was 60% and 6-(dimethylamino)-2,3-diphenyl-4(3H)-pyrimidinone (21%) was obtained as byproduct.
IT 417755-31-8P
RL: BYP (Byproduct); PREP (Preparation)
(preparation of 4(3H)-pyrimidinones via [4+2] cycloaddn. of (trimethylsilyl)ketene with 1,3-diaza-1,3-dienes)
RN 417755-31-8 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(dimethylamino)-2-(4-methylphenyl)-3-phenyl- (CA INDEX NAME)



IT 417754-93-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 4(3H)-pyrimidinones via [4+2] cycloaddn. of (trimethylsilyl)ketene with 1,3-diaza-1,3-dienes)
RN 417754-93-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-methylphenyl)-3-phenyl- (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1987:407151 CAPLUS
DN 107:7151
OREF 107:1319a,1322a
TI Heteroatom rearrangements. S,N, O,N, and N,N double rearrangements. X-ray molecular structure of 5-cyano-6-(methylthio)-2,3-diphenylpyrimidin-4(3H)-one
AU Yokoyama, Masataka; Hatanaka, Hidekatsu; Sasaki, Atsuhi; Shiraishi, Tadashi; Kumata, Katsushi; Sakamoto, Kayoko; Ogata, Koreharu
CS Fac. Sci., Chiba Univ., Chiba, 260, Japan
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1986), (7), 1187-96
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 107:7151
AB Cyclocondensation of MeSCR:C(CN)CONH2 (I; R = OH) with R1CO2H (R1 = Ph, 4-MeOC6H4, 4-ClC6H4, 4-O2NC6H4, 2-naphthyl, 2-furyl) in the presence of P2O5-(Me3Si)2O complex gave oxazinones II in 49-79% yields. Reaction of I [R = NHPh) with R1CO2H (R1 = Ph, 4-O2NC6H4, 4-ClC6H4) under the same conditions gave pyrimidinones III and IV. The mol. structure of III (R1=Ph) was determined by x-ray crystal structure anal. The reactions of I involve acylation of the cyano group, followed by transfer of the SMe group and ring closure.
IT 97242-70-1P 107427-92-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 97242-70-1 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-2-(4-nitrophenyl)-6-oxo-1-phenyl- (CA INDEX NAME)



RN 107427-92-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-chlorophenyl)-1,6-dihydro-4-(methylthio)-6-oxo-1-phenyl- (CA INDEX NAME)



L17 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1985:437445 CAPLUS
DN 103:37445
OREF 103:6075a,6078a
TI O,N and N,N double rearrangement
AU Yokoyama, Masatake; Hatanaka, Hidekatsu; Sakamoto, Kayoko
CS Dep. Chem., Chiba Univ., Chiba City, 260, Japan
SO Journal of the Chemical Society, Chemical Communications (1985), (5), 279-80
CODEN: JCCCAT; ISSN: 0022-4936
DT Journal
LA English
OS CASREACT 103:37445
AB MeSCR:C(CN)CONH2 (I; R = OH) condensed with BzOH in the presence of polyphosphoric acid trimethylsilyl ester (PPSE) gave 77% O,N-double rearranged product II (X =O), whereas similar condensation of I (R = NHPh) with BzOH in the presence of PPSE gave 49% N,N-double rearranged product III. Similar reactions occurred with other aromatic carboxylic acids and the mechanism of these heteroatom rearrangements are analogous to that of S,N-double rearrangement.
IT 97242-70-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 97242-70-1 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,6-dihydro-4-(methylthio)-2-(4-nitrophenyl)-6-oxo-1-phenyl- (CA INDEX NAME)



L17 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1978:50401 CAPLUS
DN 88:50401
OREF 88:7945a,7948a
TI Chemistry of imino esters and amidines. 11. Reaction of some amidines with malonating agents
AU Shchavlinskii, A. N.; Samoletov, M. M.; Dashkevich, L. B.; Kul'bitskii, G. N.; Tarasov, B. P.
CS Leningr. Khim.-Farm. Inst., Leningrad, USSR
SO Izvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Tekhnologiya (1977), 20(9), 1319-22
CODEN: IVUKAR; ISSN: 0579-2991
DT Journal
LA Russian
OS CASREACT 88:50401
AB PhNHCR:NH (I; R = Ph) reacted with C3O2 at 35-40° or with malonic ester at 110-15° o give 70-85% (PhNHCR:NCO)2CH2 and 1-4% tetrahydropyrimidinedione II. Analogous treatment of I [R = 4-MeOC6H4, 3,4,5-(MeO)3C6H2] afforded the corresponding II in 60-83% yield. II exist as the enolized tautomers shown with intermol. CO···HO H bonds, according to their IR and NMR spectra.
IT 65249-17-4P 65249-18-5P 65249-19-6P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and tautomerism of, spectra in relation to)
RN 65249-17-4 CAPLUS
CN 4(3H)-Pyrimidinone, 6-hydroxy-2-(4-hydroxyphenyl)-3-phenyl- (CA INDEX NAME)

102(b)



RN 65249-18-5 CAPLUS
CN 4(3H)-Pyrimidinone, 6-hydroxy-2-(4-methoxyphenyl)-3-phenyl- (CA INDEX NAME)



RN 65249-19-6 CAPLUS
CN 4(3H)-Pyrimidinone, 6-hydroxy-3-phenyl-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)


HO
N
N
Ph
O
OMe
OMe
OMe

L17 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1957:39274 CAPLUS
DN 51:39274
OREF 51:7380a-i
TI Synthesis of 2,3,5,6-substituted 4-pyrimidones
AU Staskun, Benjamin; Stephen, Henry
CS Univ. Witwatersrand Johannesburg, S. Afr.
SO Journal of the Chemical Society (1956) 4708-10
CODEN: JCSOA9; ISSN: 0368-1769
DT Journal
LA Unavailable
OS CASREACT 51:39274
AB 2,3,5,6-Substituted 4-pyrimidones (I) were readily synthesized by condensation of imidoyl chlorides (II) with Me or Et α-alkyl-β-aminocrotonates (III). The following general procedure was used: II (0.01 mole) and III (0.005, 0.01, or 0.02 mole) were refluxed 3-4 hrs. in 40 cc. dry CHCl3 (method A) or allowed to remain at room temperature 2-3 days (method B). In some cases II and III were heated in the absence of a solvent (method C), HCl and alc. being evolved. The products were acidified with dilute HCl and steam distilled; this hydrolyzed any unchanged ester to steam volatile or H2O soluble products, and converted unchanged II to the amide. After cooling, the latter was removed, and the filtrate treated with C and NH3 deposited crude I which crystallized from dilute MeOH or alc. in colorless needles. The following I were prepared by the above methods (R and R substituents in II (RCCl:NR'), R'' and X in III (MeC(NH2):CR''CO2X), molar ratio II:III, method, reaction temperature, reaction time in hrs., % yield, and m.p. given): Ph, Ph, Me, Me, 1:1, C, 140°, 0.5, -, -; Ph, Ph, Me, Et, 1:1, C, 140°, 0.5, 45, 157°; Ph, Ph, Et, Et, 1:2, A, -, 4, 79, 159°; Ph, o-C6H4Me, Me, Me, 1:1, A, -, 3, 53, 114°; Ph, o-C6H4Me, Et, Et, 1:2, A, -, 4, 80, 152°; Ph, m-C6H4Me, Me, Me, 1:1, C, 100°, 0.5, 31, 129°; Ph, m-C6H4Me, Me, Et, 1:1, C, 100°, 0.5, 28, -; Ph, m-C6H4Me, Et, Me, 1:1, C, 100°, 0.5, 77, 136°; Ph, m-C6H4Me, Et, Et, 1:2, A, -, 3, -, -; Ph, p-C6H4Me, Me, Me, 1:2, A, -, 3, 77, 146°; Ph, p-C6H4Me, Et, Et, 1:2, B, -, 3, 75, 152°; Ph, 2,4,1-Me2C6H3, Me, Me, 2:1, A, -, 3, 83, 152°; Ph, 2,4,1-Me2C6H3, Me, Et, 2:1, A, -, 3, -, -; Ph, 2,4,1-Me2C6H3, Et, Et, 2:1, A, -, 3, 83, 146°; Ph, p-MeOC6H4, Et, Et, 1:2, B, -, 3, 81, 161°; Ph, p-MeOC6H4, Pr, Me, 1:2, C, 155°, 0.5, 55, 163°; Ph, m-O2NC6H4, Me, Me, 1:2, C, 140°, 0.5, 62, 159°; Ph, m-O2NC6H4, Me, Et, 1:2, C, 140°, 0.5, 34, -; Ph, m-O2NC6H4, Et, Me, 1:2, C, 140°, 0.5, 24, 160°; Ph, m-O2NC6H4, Et, Et, 1:2, C, 140°, 0.5, 38, -; Ph, 1-C10H7, Me, Et, 1:2, A, -, 3, 64, 174°; Ph, 2-C10H7, Me, Et, 1:2, A, -, 3, 50, 189°; Ph, 2-C10H7, Et, Et, 1:2, A, -, 3, 40, 184°; Ph, o-C6H4Cl, Me, Et, 2:1, A, -, 3, 13, 151°; Ph, o-C6H4Cl, Et, Et, 2:1, C, 170°, 0.5, 32, 192°; Ph, m-C6H4Cl, Me, Me, 1:1, C, 150°, 0.5, 35, 152°; Ph, p-C6H4Cl, Et, Et, 1:2, C, 185°, 0.5, 59, 148°; Ph, p-C6H4Cl, Pr, Me, 1:2, C, 185°, 0.5, 37, 154°; Ph, Et, Et, Et, 1:2, B, -, 3, 73, 82°; Ph, Et, Me, Et, 1:2, B, -, 3, 51, 118°; o-C6H4Me, Ph, Me, Me, 2:1, A, -, 3, 80, 112°; o-C6H4Me, Ph, Et, Et, 2:1, A, -, 3, 74, 137°; p-C6H4Cl, Ph, Et, Et, 1:2, C, 155°, 0.5, 67, 146°; p-C6H4Cl, Ph, Pr, Me, 1:2, C, 155°, 0.5, 21, 151°; 3,4,5-(MeO)3C6H2, Ph, Me, Me, 1:2, A, -, 3, 20, 181°; 3,4,5-(MeO)3C6H2, Ph, Et, Et, 1:2, A, -, 3, 37, 129°. The

synthesis of I was modified by preparing II by rearrangement of ketoximes (IV) with PCl5. The following procedures were used. A solution of IV (0.01 mole) in 50 cc. CHCl3 was treated at 0° with 0.01 mole PCl5, the whole shaken 1-2 min., and the solution treated by one of the following procedures. The solution refluxed 15 min. to complete the rearrangement of IV, the III (0.02-0.03 mole) added in 10 cc. CHCl3, and reflux continued 2-3 hrs. (method D). Alternatively, the solution after remaining 2 hrs. at room temperature was cooled to 10°, the III (0.02-0.03 mole) in 10 cc. CHCl3 added, and the mixture left 1-2 days at room temperature (method E). The following method (F) gave good yields of I. The solution of rearranged IV, after 2 hrs. at room temperature was distilled at 40-5°/30 min., then stored 1-2 days with 0.02-0.03 mole III, and the products treated as previously described. I were crystallized as colorless needles from MeOH or alc. The following results were obtained (IV, R'' in III, method, % yield, and m.p. of I given): PhMeC:NOH, Et, E, 65, 126°; (p-MeC6H4)MeC:NOH, Et, E, 65, 82°; (p-MeC6H4)MeC:NOH, Me, D, 65, 146°; 2-C10H7CMe:NOH, Et, F, 65, 130°; PhPrC:NOH, Et, E, 72, 106°; PhPrC:NOH, Me, E, 35, 73°; (p-MeC6H4)2C:NOH, Me, F, 73, 128°; (p-MeC6H4)2C:NOH, Et, F, 60, 140°; Ph2C:NOH, Et, D, 55, 157°. Improved yields of I were obtained by using excess II or III.

IT 102316-51-8P, 4(3H)-Pyrimidinone, 5,6-dimethyl-2,3-di-p-tolyl-
102660-46-8P, 4(3H)-Pyrimidinone, 5-ethyl-6-methyl-2,3-di-p-tolyl-
102660-83-3P, 4(3H)-Pyrimidinone,
5,6-dimethyl-3-phenyl-2-(3,4,5-trimethoxyphenyl)- 102810-25-3P,
4(3H)-Pyrimidinone, 5-ethyl-6-methyl-3-phenyl-2-(3,4,5-trimethoxyphenyl)-
103755-10-8P, 4(3H)-Pyrimidinone,
2-(p-chlorophenyl)-6-methyl-3-phenyl-5-propyl- 109809-97-4P,
4(3H)-Pyrimidinone, 2-(p-chlorophenyl)-5-ethyl-6-methyl-3-phenyl-
110144-94-0P, 4(3H)-Pyrimidinone, 5,6-dimethyl-3-phenyl-2-o-tolyl-
110244-34-3P, 4(3H)-Pyrimidinone,
5-ethyl-6-methyl-3-phenyl-2-o-tolyl-
RL: PREP (Preparation)
(preparation of)

RN 102316-51-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5,6-dimethyl-2,3-bis(4-methylphenyl)- (CA INDEX NAME)



RN 102660-46-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5-ethyl-6-methyl-2,3-bis(4-methylphenyl)- (CA INDEX NAME)



RN 102660-83-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5,6-dimethyl-3-phenyl-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 102810-25-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-ethyl-6-methyl-3-phenyl-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 103755-10-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chlorophenyl)-6-methyl-3-phenyl-5-propyl- (CA INDEX NAME)



RN 109809-97-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-chlorophenyl)-5-ethyl-6-methyl-3-phenyl- (CA INDEX NAME)



RN 110144-94-0 CAPLUS
CN 4(3H)-Pyrimidinone, 5,6-dimethyl-2-(2-methylphenyl)-3-phenyl- (CA INDEX NAME)



RN 110244-34-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-ethyl-6-methyl-2-(2-methylphenyl)-3-phenyl- (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    96.88     288.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -13.94     -13.94

STN INTERNATIONAL LOGOFF AT 14:08:10 ON 27 FEB 2009
```